Chief Scientific Officer
Dr. Kandimalla has served as our Chief Scientific Officer since October 2015, bringing over 20 years of discovery research and preclinical drug development experience. Dr. Kandimalla has led discovery of oligonucleotide therapeutics targeting mRNA, miRNA and Toll-like receptors for the treatment of broad disease indications, including cancers, asthma-allergies, autoimmune, cardiovascular and metabolic diseases. Dr. Kandimalla has extensive experience in oligonucleotide chemistry, in vitro and in vivo pharmacology, target identification and validation to late stage discovery. Prior to joining Exicure, Dr. Kandimalla served as Chief Scientific Officer of ChemGenes Corporation for over a year. Dr. Kandimalla was at Idera Pharmaceuticals Inc. (formerly Hybridon, Inc.) from June 1992 to November 2012, in various roles of increasing responsibility, most recently as Vice President of discovery, where he was responsible for generating new product pipeline, support early drug development, establish and maintain external scientific collaborations. Prior to joining Hybridon, Dr. Kandimalla has carried out postdoctoral research at Molecular Biophysics Unit of Indian Institute of Science, and Department of Chemistry of the University of Alberta. Dr. Kandimalla is an author on over 150 publications, including reviews and book chapters, and a co-inventor on about 300 issued/pending patents worldwide. Dr. Kandimalla has a Ph.D. in Chemistry, M.Sc. in Biochemistry and B.Sc. in Chemistry, all from Andhra University, India.